Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Sensitivity to a neurosteroid is increased during addition of progestagen to postmenopausal hormone replacement therapy
Autore:
Wihlback, AC; Sundstrom-Poromaa, I; Nyberg, S; Backstrom, T;
Indirizzi:
Umea Univ Hosp, Dept Clin Sci Obstet & Gynecol, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 bstet & Gynecol, S-90185 Umea, Sweden
Titolo Testata:
NEUROENDOCRINOLOGY
fascicolo: 6, volume: 73, anno: 2001,
pagine: 397 - 407
SICI:
0028-3835(200106)73:6<397:STANII>2.0.ZU;2-M
Fonte:
ISI
Lingua:
ENG
Soggetto:
PREMENSTRUAL-SYNDROME; ESTROGEN REPLACEMENT; DOUBLE-BLIND; BENZODIAZEPINE SENSITIVITY; NEUROACTIVE STEROIDS; CONTROLLED TRIAL; MENSTRUAL-CYCLE; EYE-MOVEMENTS; PROGESTERONE; WOMEN;
Keywords:
gonadal steroids; neuroactive steroids; saccadic eye velocity; sedation; hormone replacement therapy; menopause; clinical neuroendocrinology; mood;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Wihlback, AC Umea Univ Hosp, Dept Obstet & Gynecol, S-90185 Umea, Sweden Umea Univ Hosp Umea Sweden S-90185 ol, S-90185 Umea, Sweden
Citazione:
A.C. Wihlback et al., "Sensitivity to a neurosteroid is increased during addition of progestagen to postmenopausal hormone replacement therapy", NEUROENDOCR, 73(6), 2001, pp. 397-407

Abstract

The aim of this study was to compare the pharmacodynamic response to a neuroactive steroid, pregnanolone, before and during different hormonal settings of postmenopausal hormone replacement therapy (HRT). Twenty-seven postmenopausal women with climacteric symptoms were administered HRT in a randomized, double-blinded, placebo-controlled crossover study. The women received2 mg estradiol (E-2) continuously during four 28-day cycles and 10 mg medroxyprogesterone acetate (MPA), 1 mg norethisterone acetate (NETA) or placebo sequentially for the last 14 days in each cycle, The pharmacodynamic response to pregnanolone was assessed before treatment and during the last weekof each treatment, by comparing the effects of intravenous pregnanolone (3alpha -hydroxy-5 beta -pregnan-20-one) on saccadic eye velocity (SEV), saccade deceleration, saccade latency and self-rated sedation. Throughout the study daily symptom rating scales were kept. During the progesta gen phase of the treatment cycles, negative mood symptoms and physical symptoms were increased, whereas positive mood symptoms were decreased. Compared to pretretreatment conditions, E-2 alone did not change the responsiveness to pregnanolone. During progestagen addition to E-2, the responsiveness to pregnanolone was increased. The sedation response increased compared to pretreatment conditions during both E-2 + MPA and E-2 + NETA treatment. Compared to E-2 treatment alone, addition of MPA increased the postpregnanolone effect onsaccade deceleration, whereas the SEV response to pregnanolone was increased during E-2 + NETA treatment. It is concluded that pregnanolone sensitivity increases together with deterioration in mood symptoms during addition of progestagen to HRT. Copyright (C) 2001 S. Karger AG, Basel.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 16:14:09